Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

0001645666

Kezar Life Sciences develops first-in-class, small molecule therapies targeting key intracellular proteins to inhibit disease-driving cellular pathways. They focus on Selective Immunoproteasome Inhibition for autoimmune diseases and Protein Secretion Inhibition for cancer and autoimmune diseases. Their mission is to deliver unique treatments for difficult-to-treat chronic diseases.

90
Altamente Confiable
Puntuación de Confianza

Registro Oficial

Nombre Legal
Kezar Life Sciences, Inc.
Número de organización
0001645666
Número de IVA
473366145
Estado de la Empresa
Active
Dirección
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA 94080
Códigos de Industria
2834: Pharmaceutical Preparations

Última verificación: 1/2/2026

Análisis de Calidad IA

Industria
Biotechnology
SSL/HTTPS
Seguro
Correo profesional
Correo de contacto
contact@kezarbio.com

🌟 Empresas similares de confianza

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Altamente Confiable

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, Estados Unidos
Ver perfil

AGENUS INC

AGENUS INC logo
86/100 · Altamente Confiable

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, Estados Unidos
Ver perfil

Evaxion A/S

Evaxion A/S logo
77/100 · Confiable

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, Estados Unidos
Ver perfil